Withanolide D Exhibits Similar Cytostatic Effect in Drug-Resistant and Drug-Sensitive Multiple Myeloma Cells
Overview
Affiliations
In spite of recent therapeutic advances, multiple myeloma (MM) remains a malignancy with very low curability. This has been partly attributed to the existence of a drug-resistant subpopulation known as cancer stem cells (CSCs). MM-CSCs are equipped with the necessary tools that render them highly resistant to virtually all conventional therapies. In this study, the growth inhibitory effects of withanolide D (WND), a steroidal lactone isolated from , on drug-sensitive tumoral plasma cells and drug-resistant MM cells have been investigated. In MTT/XTT assays, WND exhibited similar cytostatic effects between drug-resistant and drug-sensitive cell lines in the nM range. WND also induced cell death and apoptosis in MM-CSCs and RPMI 8226 cells, as examined by the calcein/ethidium homodimer and annexin V/propidium iodide stainings, respectively. To determine whether P-glycoprotein (P-gp) efflux affected the cytostatic activity of WND, P-gp was inhibited with verapamil and results indicated that the WND cytostatic effect in MM-CSCs was independent of P-gp efflux. Furthermore, WND did not increase the accumulation of the fluorescent P-gp substrate rhodamine 123 in MM-CSCs, suggesting that WND may not inhibit P-gp at the tested relevant doses. Therefore, the WND-induced cytostatic effect may be independent of P-gp efflux. These findings warrant further investigation of WND in MM-CSC animal models.
Abdullah Al Awadh A, Sakagami H, Amano S, Sayed A, Abouelela M, Alhasaniah A Front Pharmacol. 2024; 15:1325272.
PMID: 38303989 PMC: 10830635. DOI: 10.3389/fphar.2024.1325272.
Kapoor S, Gupta N, Sharma A Asian Pac J Cancer Prev. 2023; 24(11):3705-3714.
PMID: 38019228 PMC: 10772745. DOI: 10.31557/APJCP.2023.24.11.3705.
: Progress towards a Pharmaceutical Agent for Immunomodulation and Cancer Therapeutics.
Kashyap V, Peasah-Darkwah G, Dhasmana A, Jaggi M, Yallapu M, Chauhan S Pharmaceutics. 2022; 14(3).
PMID: 35335986 PMC: 8954542. DOI: 10.3390/pharmaceutics14030611.
Lacombe J, Cretignier T, Meli L, Wijeratne E, Veuthey J, Cuendet M Front Oncol. 2020; 9:1468.
PMID: 31970089 PMC: 6960174. DOI: 10.3389/fonc.2019.01468.
Mu X, Shi W, Xu Y, Xu C, Zhao T, Geng B Cell Cycle. 2018; 17(4):428-438.
PMID: 29468929 PMC: 5927648. DOI: 10.1080/15384101.2018.1444305.